Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Place in treatment, anticipated use, and care setting
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Approaches to treatment

Place in treatment, anticipated use, and care setting

6 evidence topics · 3 sources

First FDA-approved ophthalmic bevacizumab formulation

“rigorous clinical evidence, validated manufacturing, approved labeling, comprehensive quality systems, and ongoing FDA regulatory oversight” (opens the source at this quote in a new tab)
“Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve.” (opens the source at this quote in a new tab)

Relationship to compounded/repackaged bevacizumab

“Bevacizumab has long been used off-label as an anti-VEGF therapy for retinal diseases because of its comparatively low cost, despite lacking an FDA-approved ophthalmic formulation.” (opens the source at this quote in a new tab)

Manufacturer statement on positioning

“It's really been the retina community that has been supporting us and steadfast in sustaining us through this journey because they've been requesting and wanting an FDA-approved [formulation of bevacizumab],” (opens the source at this quote in a new tab)
“this is a bevacizumab that has been specifically designed for ophthalmology use, which I think is really important.” (opens the source at this quote in a new tab)

Commercial launch plans and care setting

“Outlook Therapeutics expects to make LYTENAVA™ available to eligible patients in the United States before year-end” (opens the source at this quote in a new tab)

Market context into which Lytenava enters

“The U.S. anti-VEGF retina market is estimated at approximately $8.5 billion annually, with millions of intravitreal injections administered every year.” (opens the source at this quote in a new tab)

FDA-licensed indication

“Lytenava is indicated for treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).” (opens the source at this quote in a new tab)